The secretory phospholipase A2 group IIA: A missing link between inflammation, activated renin-angiotensin system, and atherogenesis?

Vascular Health and Risk Management

Volumn 4, Issue 3, 2008, Pages 597-604

  Divchev, Dimitar ^a   Schieffer, Bernhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Atherosclerosis; Inflammation; Lipoproteins; Renin angiotensin system; Secretory phospholipase A2

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN A1; IRBESARTAN; LOSARTAN; LOW DENSITY LIPOPROTEIN; LY 311727; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; PRAVASTATIN; ANGIOTENSIN 1 RECEPTOR; PHOSPHOLIPASE A2 GROUP II;

ACUTE CORONARY SYNDROME; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG MECHANISM; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INFLAMMATION; LIPID METABOLISM; LIPID PEROXIDATION; LIPID STORAGE; NONHUMAN; PROGNOSIS; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS; BLOOD; MACROPHAGE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; GROUP II PHOSPHOLIPASES A2; HUMANS; INFLAMMATION; LIPID PEROXIDATION; MACROPHAGES; PROGNOSIS; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM;

EID: 47849087359     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Antonio V, Brouillet A, Janvier B, et al. 2002. Transcriptional regulation of the rat type IIA phospholipase A2 gene by cAMP and interlieukin-1b in vascular smooth muscle cells: interplay of the CCAAT/ enhancer binding protein (C/EBP), nuclear factor-kB and Ets transcription factors. Biochem J, 368:415-24.
2. Arbibe L, Koumanov K, Vial D, et al. 1998. Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by a direct surfactant protein A-phospholipase A2 protein interaction. J Clin Invest. 102:1152-60.
3. Aviram M, Maor I. 1992. Phospholipase A2-modified LDL is taken up at enhanced rate by macrophages. Biochim Biophys Res Commun, 185:465-72.
4. Balboa MA, Balsinde J, Winstead MV, et al. 1996. Novel group V phospholipase A2 involved in arachidonic acid mobilization in murine P388D1 macrophages. J Biol Chem, 271:32381-4.
5. Balsinde J, Dennis EA. 1997. Inflammatory activation of arachidonic acid signaling in murine P388D1 macrophages via sphingomyelin synthesis. J Biol Chem, 272:20373-7.
6. Barbour SE, Dennis EA. 1993. Antisense inhibition of group II phospholipase A2 expression blocks the production of prostaglandin E2 by P388Dresden cells. J Biol Chem, 268:21875-82.
7. Bezzine S, Koduri RS, Valentin E, et al. 2000. Exogenously added human group X secreted phospholipase A2 but not the group IB, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells. J Biol Chem, 275:3179.
8. Boekholdt SM, Keller TT, Wareham NJ, et al. 2005. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women The EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol, 25:839-46.
9. Bonventre JV. 1999. The 85-kD cytosolic phospholipase A2 knockout mouse: a new tool for physiology and cell biology. J Am Soc Nephrol, 10:404-12.
10. Cassis LA, Rateri DL, Lu H, et al. 2007. Bone marrow transplantation reveals that recipient AT1a receptors are requiredto initiate Angiotensin II-induced atherosclerosis and aneurysms. Arterioscler Thromb Vasc Biol, 27:380-6.
11. Crowl RM, Stoller TJ, Conroy RR, et al. 1991. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute-phase response. J Biol Chem, 266:2647-51.
12. de Beer FC, de Beer MC, van der Westhuyzen DR, et al. 1997. Secretory non-pancreatic phospholipase A2: influence on lipoprotein metabolism. J Lipid Res, 38:2232-9.
13. de Beer FC, Connell PM, Yu J, et al. 2000. HDL modification by secretory phospholipase A2 promotes scavenger receptor class B type I interaction and accelerates HDL catabolism. J Lipid Res, 41:1849-57.
14. Divchev D, Grothusen Ch, Luchtefeld M, et al. Personal communication. Impact of a combined treatment of angiotensin II type 1 receptor blockade and HMG-CoA-reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease. Eur Heart J, Manuscript Number: EURHEARTJ-D-07-01269, under review.
15. Eckey R, Menschikowski M, Lattice P, et al. 1997. Minimal oxidation and storage of low density lipoproteins result in an increased susceptibility to phospholipid hydrolysis by phospholipase A2. Atherosclerosis, 132:165-76.
16. Fonteh AN, Bass DA, Marshall LA, et al. 1994. Evidence that secretory phospholipase A2 plays a role in arachidonic acid release and eicosanoid biosynthesis by mast cells. J Immunol, 152:5438-46.
17. Fourcade O, Le Balle F, Fauvel J, et al. 1998. Regulation of secretory type-II phospholipase A2 and of lysophosphatidic acid synthesis. Adv Enzyme Regul, 38:99-107.
18. Gesquiere L, Cho W, Subbaiah PV. 2002. Role of group IIA and group V secretory phospholipases A2 in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin. Biochemistry, 41:4911-20.
19. Granata F, Balestrieri B, Petraroli A, et al. 2003. Secretory phospholipases A2 as multivalent mediators of inflammatory and allergic disorders. Int Arch Allergy Immunol, 131:153.
20. Green JA, Smith GM, Buchta R, et al. 1991. Circulating phospholipase A2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis. Inflammation, 15:355-67.
21. Hakala JK, Oorni K, Pentikamen MO. 2001. Lipolysis of LDL by human secretory phospholipase A2 induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler Thromb Vasc Biol, 21:1053-8.
22. 2 alpha activity that is responsible for arachidonic acid release. J Biol Chem, 278:24153-63.
23. Hanasaki K, Yamada K, Yamamoto S, et al. 2002. Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. J Biol Chem, 277:29116.
24. Hayakawa M, Kudo, I, Tomita M, et al. 1988. Purification and characterization of membrane-bound phospholipase A2 from rat platelets. J Biochem (Tokyo), 103:263-6.
25. Hayek T, Aviram M, Heinrich R, et al. 2000. Losartan Inhibits Cellular Uptake of Oxidized LDL by Monocyte-Macrophages from Hypercholesterolemic Patients. Biochemical and Biophysical Research Communications, 273:417-20.
26. Heinecke JW, Suits AG, Aviram M, et al. 1991. Phagocytosis of lipase-aggregated low density lipoprotein promotes macrophage foam cell formation. Sequential morphological and biochemical events. Arterioscler Thromb, 11:1643-51.
27. Hernandez M, Burillo SL, Crespo MS, et al. 1998. Secretory phospholipase A2 activates the cascade of mitogen-activated protein kinases and cytosolic phospholipase A2 in the human astrocytoma cell line 1321N1. J Biol Chem, 273:606.
28. Hidi R, Vargaftig BB, Touqui L. 1993. Increased synthesis and secretion of a 14-kDa phospholipase A2 by guinea pig alveolar macrophages: dissociation from arachidonic acid liberation and modulation by dexamethasone. J Immunol, 151:56130-23.
29. Hurt-Camejo E, Andersen S, Standal R, et al. 1997. Localization of non-pancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins. Arterioscler Thromb Vasc Biol, 17:300-9.
30. Hurt-Camejo E, Camejo G, Peilot H, et al. 2001. Phospholipase A2 in vascular disease. Circ Res, 89:298-304.
31. Ivandic B, Castellani LW, Wang XP, et al. 1999. Role of group II secretory phospholipase A2 in atherosclerosis, 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIA phospholipase A2. Arterioscler Thromb Vasc Biol, 19:1284-90.
32. Jaross W, Eckey R, Menschikowski M. 2002. Biological effects of secretory phospholipase A(2) group IIA on lipoproteins and in atherogenesis. Eur J Clin Invest, 32:383-93.
33. Keidar S, Kaplan M, Hoffman A, et al. 1995. Ang-II stimulates macrophage-mediated oxidation of LDL. Atherosclerosis, 115:201-15.
34. Keidar S, Attias J, Smith J, et al. 1997. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipo-protein E-deficient mice. Biochem Biophys Res Comm, 236:622-5.
35. Keidar S. 1998. Angiotensin, LDL peroxidation and Atherosclerosis. Life Sciences, 63(1):1-11.
36. 0 mice is associated with increased cellular cholesterol biosynthesis. Atherosclerosis, 146:249-57.
37. Keidar S, Heinrich R, Kaplan M, et al. 2001. Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: a possible role for interleukin-6. Arterioscler Thromb Vasc Biol, 21:1464-9.
38. Korotaeva AA, Samoilova EV, Kaminny AI, et al. 2005. The catalytically active secretory phospholipase A2 type IIA is involved in restenosis development after PTCA in human coronary arteries and generation of atherogenic LDL. Mol Cell Biochem, 270:107-113.
39. Kovanen PT, Pentikamen MO. 2000. Secretory group II phospholipase A2; a newly recognized acute-phase reactant with a role in atherogenesis. Circ Res, 86:610-12.
40. Kudo I, Murakami M. 2002. Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat, 68-69:3-58.
41. Kugiyama K, Ota Y, Takazoe K, et al. 1999. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation, 100: 1280-4.
42. Kugiyama K, Ota Y, Sugiyama S, et al. 2000. Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am J Cardiol, 86:718-22.
43. Kurihara H, Nakano T, Takasu N, et al. 1991. Intracellular localization of group II phospholipase A2 in rat vascular smooth muscle cells and its possible relationship to eicosanoid formation. Biochim Biophys Acta, 1082:285-92.
44. Lame VJO, Grass DS, Nevalainen TJ. 1999. Protection by group II phospholipase A2 against Staphylococcus aureus. J Immunol, 162:7402-8.
45. Leitinger N, Watson AD, Hama SY, et al. 1999. Role of group II secretory phopholipase A2 in atherosclerosis: 2. Potential involvment of biologically active oxidized phospholipids. Arterioscler Thromb Vasc Biol, 19:1291-8.
46. Leslie CC. 1997. Properties and regulation of cytosolic phospholipase A2. J Biol Chem, 272:16709-12.
47. Liu PY, Li YH, Tsai WC, et al. 2003. Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J, 24: 1824-32.
48. Lowe LP, Greenland P, Ruth KJ, et al. 1998. Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men. Arch Intern Med, 158:2007-14.
49. Luchtefeld M, Bandlow N, Tietge UJ, et al. 2006. Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A(2)-dependent lipid peroxidation. Atherosclerosis, 25:25.
50. Mallat Z, Steg PG, Benessiano J, et al. 2005. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol, 46:1249-57.
51. Mallat Z, Benessiano J, Simon T, et al. 2007. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: The EPIC-NORFOLK Study. Arterioscler Thromb Vasc Biol, 27:1177-83.
52. Mehra JL, Li D. 2001. Facilitative interaction between angiotensin II and oxidized LDL in cultured human coronary artery endothelial cells. J Renin Angiotensin Aldosterone Syst, 2: S70-S76.
53. Mehta JL, Li D. 2002. Identification, regulation and function of a novel lectin like oxidized low density lipoprotein receptor. J Am Coll Cardiol, 39:1429-1435.
54. Menschikowski M, Eckey R, Pietzsch J, et al. 2000. Expression of human secretory group IIA phospholipase A2 is associated with reduced concentrations of plasma cholesterol in transgenic mice. Inflammation, 24:227-37.
55. Menschikowski M, Rosner-Schiering A, Eckey R, et al. 2000. Expression of secretory group IIA phospholipase A(2) in relation to the presence of microbial agents, macrophage infiltrates, and transcripts of proinflammatory cytokines in human aortic tissues. Arterioscler Thromb Vasc Biol, 20:751-62.
56. Menschikowski M, Hagelgans A, Siegert G. 2006. Secretory phospholipase A2 of group IIA: Is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases? Prostaglandins Other Lipid Mediat, 79:1-33.
57. Murakami M, Kudo I, Inoue K. 1993. Molecular nature of phospholipase A2 involved in prostaglandin I2 synthesis in human umbilical vein endothelial cells: possible participation of cytosolic and extracellular type II phospholipase A2. J Biol Chem, 268:839-44.
58. Murakami M, Kudo I. 2003. New phospholipase A2 isozymes with a potential role in atherosclerosis. Curr Opin Lipidol, 14:431-6.
59. Murakami M, Kudo I. 2004. Secretory phospholipase A2. Biol Pharm Bull, 27:1158-64.
60. Nakano T, Ohara O, Teraoka H, et al. 1990. Glucocorticoids suppress group II phospholipase A2 production by blocking mRNA synthesis and post-transcriptional expression. J Biol Chem, 265:12745-8.
61. Neaton JD, Wentworth D. 1992. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med, 152:56-64.
62. Nickenig G, Wassmann S, Bohm M. 2000. Regulation of the angiotensin AT1 receptor by hypercholesterolaemia. Diabetes Obes Metab, 2:223-8.
63. Niessen HW, Krijnen PA, Visser CA, et al. 2003. Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes? Cardiovasc Res, 60:68.
64. Peilot H, Rosengren B, Bondjers G, et al. 2000. Interferon-g induces secretory group IIA phospholipase A2 in human arterial smooth muscle cells: involvement of cell differentiation, STAT-3 activation, and modulation by other cytokines. J Biol Chem, 275:22895-904.
65. Pfeilschifter J, Pignat W, Vosbeck K, et al. 1989. Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat mesangial cells. Biochem Biophys Res Commun, 159:385-94.
66. Pickard RT, Strifler BA, Kramer RM, et al. 1999. Molecular cloning of two new human paralogs of 85-kDa cytosolic phospholipase A2. J Biol Chem, 274:8823-31.
67. Pruzanski W, Stefanski E, Vadas P, et al. 1998. Regulation of the cellular expression of secretory and cytosolic phospholipases A2, and cyclooxygenase-2 by peptide growth factors. Biochim Biophys Acta, 1403:47-56.
68. Reddy ST, Herschman HR. 1996. Transcellular prostaglandin production following mast cell activation is mediated by proximal secretory phospholipase A2 and distal prostaglandin synthase 1. J Biol Chem, 272:186-91.
69. Reddy ST, Herschman HR. 1997. Prostaglandin synthase-1 and prostaglandin synthase-2 are coupled to distinct phospholipases for the generation of prostaglandin D2 in activated mast cells. J Biol Chem, 272:3231-7.
70. Romano M, Romano E, Bjorkerud S, et al. 1998. Ultrastructural localization of secretory type II phospholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries. Arterioscler Thromb Vasc Biol, 18:519-25.
71. Rosengren B, Peilot H, Umaerus M, et al. 2004. Secretory phospholipase A2 type IIA and V in atherosclerosis: expression by vascular cells, localization in lesions and hydrolysis of lipoproteins. Atherosclerosis Suppl, 5:147.
72. Ross R. 1999. Atherosclerosis - an inflammatory disease. N Engl J Med, 340:115-26.
73. Sapirstein A, Bonventre JV. 2000. Specific physiological roles of cytosolic phospholipase A(2) as defined by gene knockouts. Biochim Biophys Acta, 1488:139-48.
74. Sartipy P, Bondjers G, Hurt-Camejo E. 1998. Phospholipase A2 type II binds to extracellular matrix biglycan: modulation of its activity on LDL by colocalization in glycosaminoglycan matrixes. Arteioscler Thromb Vasc Biol, 18:1934-41.
75. Sartipy P, Johansen B, Gasvik K, et al. 2000. Molecular basis for the association of group IIA phospholipase A2 and decorin in human atherosclerotic lesions. Circ Res, 86:707-14.
76. Schalkwijk C, Pfeilschifter J, Märki F, et al. 1991. Interleukin 1β, tumor necrosis factor and forskolin stimulate the synthesis and secretion of group II phospholipase A2 in rat mesangial cells. Biochem Biophys Res Commun, 174:268-75.
77. Shoda J, Kano M, Asano T, et al. 1999. Secretory low-molecular-weight phospholipases A2 and their specific receptor in bile ducts of patients with intrahepatic calculi: factors of chronic proliferative cholangitis. Hepatology, 29:1026-36.
78. 2 receptor on neutrophils and its role in elastase release and adhesion. Am J Physiol Cell Physiol, 283:C1102.
79. Six DA, Dennis EA. 2000. The expanding superfamily of phospholipase A2 enzymes: classification and characterization. Biochim Biophys Acta, 1488:1-19.
80. Snitko Y, Yoon ET, Cho W. 1997. High specificity of human secretory class II phospholipase A2 for phosphatidic acid. Biochem J, 321:737-41.
81. Sparrow CP, Parathasarathy S, Steinberg D. 1988. Enzymatic modification of low density lipoprotein by purified lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modification. J Lipid Res, 29:745-53.
82. Tada K, Murakami M, Kambe T, et al. 1998. Induction of cyclooxygenase-2 by secretory phospholipases A2 in nerve growth factor-stimulated rat serosal mast cells is facilitated by interaction with fibroblasts and mediated by a mechanism independent of their enzymatic functions. J Immunol, 161:5008.
83. Taniguchi H, Momiyama Y, Ohmori R, et al. 2005. Associations of plasma C-reactive protein levels with the presence and extent of coronary stenosis in patients with stable coronary artery disease; Atherosclerosis, 178:173-7.
84. Thomas F, Bean K, Guize L, et al. 2002. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. Eur Heart J, 23:528-35.
85. Tietge UJF, Maugeais C, Cain W, et al. 2000. Overexpression of Secretory Phospholipase A2 causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I*. J Biol Chem, 275:10077-84.
86. 2 results in accelerated atherogenesis by increasing oxidative stress. J Lipid Res, 46:1604.
87. Vadas P, Pruzanski W. 1993. Induction of group II phospholipase A2 expression and pathogenesis of the sepsis syndrome. Circ Shock, 39:160-7.
88. Valentin E, Ghomashchi F, Gelb MH, et al. 1999. On the diversity of secreted phospholipases A(2). Cloning, tissue distribution, and functional expression of two novel mouse group II enzymes. J Biol Chem, 274:31195-202.
89. Vial D, Senorale-Pose M, Havet N, et al. 1995. Expression of type-II phospholipase A2 in alveolar macrophages: down-regulation by an inflammatory signal. J Biol Chem, 270:17327-32.
90. Webb NR. 2005. Secretory phospholipase A2 enzymes in atherogenesis. Curr Opin Lipidol, 16:341-4.
91. 2 hydrolysis of LDL results in spontaneous particle aggregation and promotes macrophage foam cell formation. Arterioscler Thromb Vasc Biol, 24:762-7.
92. Wright GW, Ooi CE, Weiss J, et al. 1990. Purification of a cellular (granulocyte) and an extracellular (serum) phospholipase A2 that participate in the destruction of Escherichia coli in a rabbit inflammatory exudate. J Biol Chem, 265:6675-81.
93. Yuan Y, Jackson SP, Newnham HH, et al. 1995. An essential role for lysophosphatidylcholine in the inhibition of platelet aggregation by secretory phospholipase A2. Blood, 86:4166-74.